The U.S. Food and Drug Administration (FDA) has approved a new drug for the treatment of moderate-to-severe pain that is a non-opioid and carries less risks of addiction than opioids.
Journavx works to reduce pain by targeting and interfering with the pain-signaling system located in the outer parts of our nervous system, stopping pain signals from reaching the brain.
The analgesic drugs that are typically prescribed for short-term pain—such as following an injury or surgery—work by either reducing the inflammation that causes pain or changing how the brain perceives pain.
These analgesics can sometimes contain opioids, a class of drugs that derive from, or imitate, the natural pain-relieving substances found in the opium poppy plant.
Opioids, which are also sometimes called opiates, painkillers or narcotics, all work by activating nerve cells called opioid receptors that, in turn, then block pain signals from the body to the brain.
Morphine, codeine, oxycodone, hydrocodone and fentanyl are all opioids. A person using opioids over time can develop tolerance, physical dependence and opioid use disorder, with the risk of overdose.